Neutropenia management and granulocyte colony-stimulating factor use in patients with solid tumours receiving myelotoxic chemotherapy—findings from clinical practice

[1]  G. Jerusalem,et al.  [Management of febrile neutropenia in cancer patients]. , 2015, Revue medicale de Liege.

[2]  C. Flowers,et al.  Antimicrobial prophylaxis and outpatient management of fever and neutropenia in adults treated for malignancy: American Society of Clinical Oncology clinical practice guideline. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  H. Eschenburg,et al.  Abstract P1-15-02: Febrile neutropenia (FN) risk assessment and granulocyte colony-stimulating factor (G-CSF) guideline adherence in patients with breast cancer – results from a German prospective multicentre observational study (PROTECT) , 2012 .

[4]  A. Salar,et al.  The need for improved neutropenia risk assessment in DLBCL patients receiving R-CHOP-21: findings from clinical practice. , 2012, Leukemia research.

[5]  Jacob D. Jaffe,et al.  Abstract 1: Oncogenic extracellular domain mutations of ERBB2 in cancer , 2012 .

[6]  S. Loibl,et al.  Comparison of pegfilgrastim on day 2 vs. day 4 as primary prophylaxis of intense dose-dense chemotherapy in patients with node-positive primary breast cancer within the prospective, multi-center GAIN study: (GBG 33) , 2011, Supportive Care in Cancer.

[7]  S. Whyte,et al.  Granulocyte colony-stimulating factors for febrile neutropenia prophylaxis following chemotherapy: systematic review and meta-analysis , 2011, BMC Cancer.

[8]  N. Schmitz,et al.  Randomized comparison of pegfilgrastim day 4 versus day 2 for the prevention of chemotherapy-induced leukocytopenia. , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

[9]  N. Howlader,et al.  Use of colony-stimulating factors with chemotherapy: opportunities for cost savings and improved outcomes. , 2011, Journal of the National Cancer Institute.

[10]  G. Lyman,et al.  Predicting individual risk of neutropenic complications in patients receiving cancer chemotherapy , 2011, Cancer.

[11]  R. Paridaens,et al.  Risk factors for chemotherapy-induced neutropenia occurrence in breast cancer patients: data from the INC-EU Prospective Observational European Neutropenia Study , 2011, Supportive Care in Cancer.

[12]  H. Wildiers,et al.  Relative dose intensity of chemotherapy and its impact on outcomes in patients with early breast cancer or aggressive lymphoma. , 2011, Critical reviews in oncology/hematology.

[13]  J. Machiels,et al.  The use of chemotherapy regimens carrying a moderate or high risk of febrile neutropenia and the corresponding management of febrile neutropenia: an expert survey in breast cancer and non-Hodgkin's lymphoma , 2010, BMC Cancer.

[14]  J. Crawford,et al.  Hematopoietic growth factors: ESMO Clinical Practice Guidelines for the applications. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

[15]  A. Saven,et al.  Pegfilgrastim on the Same Day Versus Next Day of Chemotherapy in Patients With Breast Cancer, Non-Small-Cell Lung Cancer, Ovarian Cancer, and Non-Hodgkin's Lymphoma: Results of Four Multicenter, Double-Blind, Randomized Phase II Studies. , 2010, Journal of oncology practice.

[16]  S. Steinberg,et al.  Ten‐year follow‐up of a phase 2 study of dose‐intense paclitaxel with cisplatin and cyclophosphamide as initial therapy for poor‐prognosis, advanced‐stage epithelial ovarian cancer , 2010, Cancer.

[17]  S. Knowles,et al.  Evaluation of direct medical costs of hospitalization for febrile neutropenia , 2010, Cancer.

[18]  J. Mayordomo,et al.  Retrospective cost analysis of management of febrile neutropenia in cancer patients in Spain , 2009, Current medical research and opinion.

[19]  P. Sevelda,et al.  3036 G-CSF use and neutropenic events in patients with breast and lung tumours: data from routine clinical practice (IMPACT Solid study) , 2009 .

[20]  S. Jelić,et al.  Do the time to chemotherapy response and the dose intensity have an impact on patient outcome in advanced non-small cell lung cancer? , 2009, Journal of B.U.ON. : official journal of the Balkan Union of Oncology.

[21]  I. Chirivella,et al.  Optimal delivery of anthracycline-based chemotherapy in the adjuvant setting improves outcome of breast cancer patients , 2009, Breast Cancer Research and Treatment.

[22]  J. Bohlius,et al.  Prophylactic antibiotics or G-CSF for the prevention of infections and improvement of survival in cancer patients undergoing chemotherapy. , 2009, The Cochrane database of systematic reviews.

[23]  V. Morrison,et al.  Impact of primary prophylaxis on febrile neutropenia within community practices in the US , 2009, Journal of medical economics.

[24]  K. Gelmon,et al.  Identifying Patients at High Risk for Neutropenic Complications During Chemotherapy for Metastatic Breast Cancer With Doxorubicin or Pegylated Liposomal Doxorubicin: The Development of a Prediction Model , 2008, American journal of clinical oncology.

[25]  Z. Berneman,et al.  Achievement of optimal average relative dose intensity and correlation with survival in diffuse large B-cell lymphoma patients treated with CHOP , 2008, Annals of Hematology.

[26]  R. Paridaens,et al.  Neutropenia occurrence and predictors of reduced chemotherapy delivery: results from the INC-EU prospective observational European neutropenia study , 2008, Supportive Care in Cancer.

[27]  M. Schwenkglenks,et al.  Association of reduced relative dose intensity and survival in lymphoma patients receiving CHOP-21 chemotherapy , 2008, Annals of Hematology.

[28]  W. Eiermann,et al.  Pegfilgrastim +/- ciprofloxacin for primary prophylaxis with TAC (docetaxel/doxorubicin/cyclophosphamide) chemotherapy for breast cancer. Results from the GEPARTRIO study. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

[29]  W. Ershler,et al.  Elderly cancer patients receiving chemotherapy benefit from first-cycle pegfilgrastim. , 2007, The oncologist.

[30]  N. Kearney,et al.  EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumours. , 2006, European journal of cancer.

[31]  Thomas J. Smith,et al.  2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  G. Lyman,et al.  Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients , 2006, Cancer.

[33]  L. Leibovici,et al.  Meta-Analysis: Antibiotic Prophylaxis Reduces Mortality in Neutropenic Patients , 2005, Annals of Internal Medicine.

[34]  B. Wiens,et al.  First and subsequent cycle use of pegfilgrastim prevents febrile neutropenia in patients with breast cancer: a multicenter, double-blind, placebo-controlled phase III study. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[35]  G. Lyman,et al.  Risk of Febrile Neutropenia among Patients with Intermediate-grade non-Hodgkin's Lymphoma Receiving CHOP Chemotherapy , 2003, Leukemia & lymphoma.

[36]  M. Kris,et al.  Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer. , 1994, The New England journal of medicine.

[37]  J. Armitage,et al.  Myeloid growth factors. , 2013, Journal of the National Comprehensive Cancer Network : JNCCN.

[38]  N. Kearney,et al.  2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours. , 2011, European journal of cancer.

[39]  S. Freeman,et al.  Pretreatment haematological laboratory values predict for excessive myelosuppression in patients receiving adjuvant FEC chemotherapy for breast cancer. , 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

[40]  J. Hay,et al.  Economic Burden of Haematological Adverse Effects in Cancer Patients , 2007, Clinical drug investigation.